موافقات الدواء

Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus 1
(HIV 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg.
Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 3, or after failure of protease inhibitor (PI) containing
regimens. Although cross resistance of Efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after
failure of regimens containing Efavirenz.
For a summary of clinical and pharmacodynamic information.